tirap Search Results


gene exp tirap hs01591921 g1  (Thermo Fisher)
94
Thermo Fisher gene exp tirap hs01591921 g1
Gene Exp Tirap Hs01591921 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pm41756299-111-63--1?v=Thermo+Fisher
Average 94 stars, based on 1 article reviews
gene exp tirap hs01591921 g1 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
tlr2 tlr4 tir domain  (Novus Biologicals)
90
Novus Biologicals tlr2 tlr4 tir domain
Tlr2 Tlr4 Tir Domain, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pm30635391-76-20-29?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
tlr2 tlr4 tir domain - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
tirap  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology tirap
Figure 3 LTB4 is required <t>for</t> <t>MyD88</t> expression in phagocytes. (A) MyD88, <t>TIRAP,</t> TRIF, and TIRP protein expression in WT macrophages and in 5-LO–/– and BLT1–/– macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO–/– and BLT1–/– mac- rophages. (C) Myd88 mRNA expression in 5-LO–/– and BLT1–/– macrophages treated as in A. (B and C) Data are representative of 3 experi- ments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; #P < 0.001 versus untreated 5-LO–/–. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO–/– mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO–/– macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are rela- tive to untreated macrophages from both genotypes. (F) MyD88 protein in WT and 5-LO–/– macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO–/– macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus non–LTB4-treated stimulated WT; &P < 0.01 versus LPS or IL-1β alone.
Tirap, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/10__1172_slash_jci43302-202-27-34?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 1 article reviews
tirap - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
tlr2 4 inhibitor  (Novus Biologicals)
92
Novus Biologicals tlr2 4 inhibitor
Figure 3 LTB4 is required <t>for</t> <t>MyD88</t> expression in phagocytes. (A) MyD88, <t>TIRAP,</t> TRIF, and TIRP protein expression in WT macrophages and in 5-LO–/– and BLT1–/– macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO–/– and BLT1–/– mac- rophages. (C) Myd88 mRNA expression in 5-LO–/– and BLT1–/– macrophages treated as in A. (B and C) Data are representative of 3 experi- ments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; #P < 0.001 versus untreated 5-LO–/–. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO–/– mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO–/– macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are rela- tive to untreated macrophages from both genotypes. (F) MyD88 protein in WT and 5-LO–/– macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO–/– macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus non–LTB4-treated stimulated WT; &P < 0.01 versus LPS or IL-1β alone.
Tlr2 4 Inhibitor, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pm40400028-85-39-45?v=Novus+Biologicals
Average 92 stars, based on 1 article reviews
tlr2 4 inhibitor - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
concentration 10× tirap  (Novus Biologicals)
91
Novus Biologicals concentration 10× tirap
Figure 3 LTB4 is required <t>for</t> <t>MyD88</t> expression in phagocytes. (A) MyD88, <t>TIRAP,</t> TRIF, and TIRP protein expression in WT macrophages and in 5-LO–/– and BLT1–/– macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO–/– and BLT1–/– mac- rophages. (C) Myd88 mRNA expression in 5-LO–/– and BLT1–/– macrophages treated as in A. (B and C) Data are representative of 3 experi- ments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; #P < 0.001 versus untreated 5-LO–/–. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO–/– mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO–/– macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are rela- tive to untreated macrophages from both genotypes. (F) MyD88 protein in WT and 5-LO–/– macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO–/– macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus non–LTB4-treated stimulated WT; &P < 0.01 versus LPS or IL-1β alone.
Concentration 10× Tirap, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pmc08509240-57-19-29?v=Novus+Biologicals
Average 91 stars, based on 1 article reviews
concentration 10× tirap - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
goat anti tirap  (Novus Biologicals)
90
Novus Biologicals goat anti tirap
Figure 3 LTB4 is required <t>for</t> <t>MyD88</t> expression in phagocytes. (A) MyD88, <t>TIRAP,</t> TRIF, and TIRP protein expression in WT macrophages and in 5-LO–/– and BLT1–/– macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO–/– and BLT1–/– mac- rophages. (C) Myd88 mRNA expression in 5-LO–/– and BLT1–/– macrophages treated as in A. (B and C) Data are representative of 3 experi- ments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; #P < 0.001 versus untreated 5-LO–/–. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO–/– mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO–/– macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are rela- tive to untreated macrophages from both genotypes. (F) MyD88 protein in WT and 5-LO–/– macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO–/– macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus non–LTB4-treated stimulated WT; &P < 0.01 versus LPS or IL-1β alone.
Goat Anti Tirap, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pmc06304375-253-57-61?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
goat anti tirap - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
human tirap  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology human tirap
Figure 3 LTB4 is required <t>for</t> <t>MyD88</t> expression in phagocytes. (A) MyD88, <t>TIRAP,</t> TRIF, and TIRP protein expression in WT macrophages and in 5-LO–/– and BLT1–/– macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO–/– and BLT1–/– mac- rophages. (C) Myd88 mRNA expression in 5-LO–/– and BLT1–/– macrophages treated as in A. (B and C) Data are representative of 3 experi- ments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; #P < 0.001 versus untreated 5-LO–/–. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO–/– mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO–/– macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are rela- tive to untreated macrophages from both genotypes. (F) MyD88 protein in WT and 5-LO–/– macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO–/– macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus non–LTB4-treated stimulated WT; &P < 0.01 versus LPS or IL-1β alone.
Human Tirap, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pmc06442981__2018__201590__BURKHARD_SUPPL-40-16-24?v=Santa+Cruz+Biotechnology
Average 90 stars, based on 1 article reviews
human tirap - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
tlr2 tlr4 inhibitor  (Novus Biologicals)
91
Novus Biologicals tlr2 tlr4 inhibitor
Figure 3 LTB4 is required <t>for</t> <t>MyD88</t> expression in phagocytes. (A) MyD88, <t>TIRAP,</t> TRIF, and TIRP protein expression in WT macrophages and in 5-LO–/– and BLT1–/– macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO–/– and BLT1–/– mac- rophages. (C) Myd88 mRNA expression in 5-LO–/– and BLT1–/– macrophages treated as in A. (B and C) Data are representative of 3 experi- ments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; #P < 0.001 versus untreated 5-LO–/–. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO–/– mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO–/– macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are rela- tive to untreated macrophages from both genotypes. (F) MyD88 protein in WT and 5-LO–/– macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO–/– macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus non–LTB4-treated stimulated WT; &P < 0.01 versus LPS or IL-1β alone.
Tlr2 Tlr4 Inhibitor, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pmc07604950-93-22-24?v=Novus+Biologicals
Average 91 stars, based on 1 article reviews
tlr2 tlr4 inhibitor - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
control shrna lentiviral particles  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology control shrna lentiviral particles
Figure 3 LTB4 is required <t>for</t> <t>MyD88</t> expression in phagocytes. (A) MyD88, <t>TIRAP,</t> TRIF, and TIRP protein expression in WT macrophages and in 5-LO–/– and BLT1–/– macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO–/– and BLT1–/– mac- rophages. (C) Myd88 mRNA expression in 5-LO–/– and BLT1–/– macrophages treated as in A. (B and C) Data are representative of 3 experi- ments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; #P < 0.001 versus untreated 5-LO–/–. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO–/– mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO–/– macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are rela- tive to untreated macrophages from both genotypes. (F) MyD88 protein in WT and 5-LO–/– macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO–/– macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus non–LTB4-treated stimulated WT; &P < 0.01 versus LPS or IL-1β alone.
Control Shrna Lentiviral Particles, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pmc03528317-63-4-10?v=Santa+Cruz+Biotechnology
Average 90 stars, based on 1 article reviews
control shrna lentiviral particles - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
snp tirap c 25983622 10  (Thermo Fisher)
85
Thermo Fisher snp tirap c 25983622 10
Allele frequencies in the study population for the selected SNPs
Snp Tirap C 25983622 10, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pmc03411399-105-45--1?v=Thermo+Fisher
Average 85 stars, based on 1 article reviews
snp tirap c 25983622 10 - by Bioz Stars, 2026-08
85/100 stars
  Buy from Supplier
gene exp tirap hs00364644 m1  (Thermo Fisher)
86
Thermo Fisher gene exp tirap hs00364644 m1
Allele frequencies in the study population for the selected SNPs
Gene Exp Tirap Hs00364644 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pmc05600985__table_1-0-135--1?v=Thermo+Fisher
Average 86 stars, based on 1 article reviews
gene exp tirap hs00364644 m1 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
tirap gfp  (Addgene inc)
85
Addgene inc tirap gfp
Allele frequencies in the study population for the selected SNPs
Tirap Gfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tirap/pmc05040511-89-4-7?v=Addgene+inc
Average 85 stars, based on 1 article reviews
tirap gfp - by Bioz Stars, 2026-08
85/100 stars
  Buy from Supplier

Image Search Results


Figure 3 LTB4 is required for MyD88 expression in phagocytes. (A) MyD88, TIRAP, TRIF, and TIRP protein expression in WT macrophages and in 5-LO–/– and BLT1–/– macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO–/– and BLT1–/– mac- rophages. (C) Myd88 mRNA expression in 5-LO–/– and BLT1–/– macrophages treated as in A. (B and C) Data are representative of 3 experi- ments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; #P < 0.001 versus untreated 5-LO–/–. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO–/– mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO–/– macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are rela- tive to untreated macrophages from both genotypes. (F) MyD88 protein in WT and 5-LO–/– macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO–/– macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus non–LTB4-treated stimulated WT; &P < 0.01 versus LPS or IL-1β alone.

Journal: Journal of Clinical Investigation

Article Title: Leukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression

doi: 10.1172/jci43302

Figure Lengend Snippet: Figure 3 LTB4 is required for MyD88 expression in phagocytes. (A) MyD88, TIRAP, TRIF, and TIRP protein expression in WT macrophages and in 5-LO–/– and BLT1–/– macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO–/– and BLT1–/– mac- rophages. (C) Myd88 mRNA expression in 5-LO–/– and BLT1–/– macrophages treated as in A. (B and C) Data are representative of 3 experi- ments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; #P < 0.001 versus untreated 5-LO–/–. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO–/– mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO–/– macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are rela- tive to untreated macrophages from both genotypes. (F) MyD88 protein in WT and 5-LO–/– macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO–/– macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus non–LTB4-treated stimulated WT; &P < 0.01 versus LPS or IL-1β alone.

Article Snippet: Protein samples were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with commercially available primary antibodies against MyD88, TRIF, TIRP, SOCS1 (all 1:500, Abcam); p65, TIRAP, phosphorylated IκBα, p50, p65 (all 1:500, Santa Cruz); Tyr701and Ser727-phosphorylated as well as total STAT1, STAT3, and JAK2 and phosphorylated JAK2 (Tyr1007/1008), JAK1 (Tyr1022/1023), Tyk2 (Tyr1052/1053), and STAT3 (Tyr705) (all 1:1,000; Cell Signaling); and β-actin (1:10,000; Sigma-Aldrich).

Techniques: Expressing, Control, Incubation, Western Blot

Allele frequencies in the study population for the selected SNPs

Journal: Malaria Journal

Article Title: Role of polymorphisms of toll-like receptor (TLR) 4, TLR9, toll-interleukin 1 receptor domain containing adaptor protein (TIRAP) and FCGR2A genes in malaria susceptibility and severity in Burundian children

doi: 10.1186/1475-2875-11-196

Figure Lengend Snippet: Allele frequencies in the study population for the selected SNPs

Article Snippet: The non-synonymous SNP of TLR4 Asp299Gly (rs4986790, assay code C__11722238_20), the intronic SNP of TLR-9 G(1174)A (rs352139, assay code C___2301953_10), the two promoter SNPs of TLR-9 at positions T(-1486)C (rs187084, assay code C___2301952_10) and T(-1237)C (rs5743836, assay code C__32645383_10), the TIRAP/MAL Ser180Leu (rs8177374, assay code C__25983622_10) and the FCGR2A His131Arg non- synonyimous SNPs (rs1801274, assay code C___9077561_20) were then studied.

Techniques: Ubiquitin Proteomics

Genotype frequencies comparing uninfected controls and children with malaria for the selected SNPs

Journal: Malaria Journal

Article Title: Role of polymorphisms of toll-like receptor (TLR) 4, TLR9, toll-interleukin 1 receptor domain containing adaptor protein (TIRAP) and FCGR2A genes in malaria susceptibility and severity in Burundian children

doi: 10.1186/1475-2875-11-196

Figure Lengend Snippet: Genotype frequencies comparing uninfected controls and children with malaria for the selected SNPs

Article Snippet: The non-synonymous SNP of TLR4 Asp299Gly (rs4986790, assay code C__11722238_20), the intronic SNP of TLR-9 G(1174)A (rs352139, assay code C___2301953_10), the two promoter SNPs of TLR-9 at positions T(-1486)C (rs187084, assay code C___2301952_10) and T(-1237)C (rs5743836, assay code C__32645383_10), the TIRAP/MAL Ser180Leu (rs8177374, assay code C__25983622_10) and the FCGR2A His131Arg non- synonyimous SNPs (rs1801274, assay code C___9077561_20) were then studied.

Techniques:

Genotype frequencies comparing uninfected controls and children with malaria for the selected SNPs

Journal: Malaria Journal

Article Title: Role of polymorphisms of toll-like receptor (TLR) 4, TLR9, toll-interleukin 1 receptor domain containing adaptor protein (TIRAP) and FCGR2A genes in malaria susceptibility and severity in Burundian children

doi: 10.1186/1475-2875-11-196

Figure Lengend Snippet: Genotype frequencies comparing uninfected controls and children with malaria for the selected SNPs

Article Snippet: The non-synonymous SNP of TLR4 Asp299Gly (rs4986790, assay code C__11722238_20), the intronic SNP of TLR-9 G(1174)A (rs352139, assay code C___2301953_10), the two promoter SNPs of TLR-9 at positions T(-1486)C (rs187084, assay code C___2301952_10) and T(-1237)C (rs5743836, assay code C__32645383_10), the TIRAP/MAL Ser180Leu (rs8177374, assay code C__25983622_10) and the FCGR2A His131Arg non- synonyimous SNPs (rs1801274, assay code C___9077561_20) were then studied.

Techniques: